Actively Recruiting
Phase 12 Study of BMS-986340 Alone and Combined with Nivolumab, Docetaxel, or Pumitamig in Adults with Advanced Solid Tumors
Led by Bristol-Myers Squibb · Updated on 2026-06-30
1109
Participants Needed
47
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating BMS-986340 alone and combined with nivolumab, docetaxel, or pumitamig in people with advanced solid tumors. This first-in-human study aims to assess the safety, tolerability, and recommended doses of BMS-986340 in participants with various advanced cancers who have progressed after standard treatments. This study includes different phases and treatment parts to explore dosing and effects. Participants receive BMS-986340 either as monotherapy or combined with nivolumab, docetaxel, or pumitamig at specified doses on scheduled days. The study includes dose escalation and expansion phases for each treatment combination. The treatments are given sequentially, with participants assigned randomly to different parts of the study to evaluate safety and dosing. During the trial, participants undergo tumor biopsies for biomarker analysis and have measurable disease per standard criteria. Researchers monitor adverse events, serious side effects, and dose-limiting toxicities up to 120 weeks. Pharmacokinetics, immune responses, and tumor responses are regularly assessed. Participants are followed for safety, disease control, and progression-free survival for up to 120 weeks.
CONDITIONS
Brief Title
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
